Ginkgo Bioworks Holdings (MEX:DNA) Current Deferred Revenue: MXN269 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:DNA Ginkgo Bioworks Holdings Inc MEX:DNA
54 GF Score
Price MXN170.00
GF Value MXN149.41
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Ginkgo Bioworks Holdings Current Deferred Revenue?

Ginkgo Bioworks Holdings MEX:DNA 54 Current Deferred Revenue is MXN269 Mil as of Mar. 2026. GuruFocus rates MEX:DNA with a GF Score™ of 54/100 and a GF Value™ of MXN149.41 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Ginkgo Bioworks Holdings's current deferred revenue for the quarter that ended in Mar. 2026 was MXN269 Mil.

Ginkgo Bioworks Holdings Current Deferred Revenue Related Terms

Ginkgo Bioworks Holdings Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Ginkgo Bioworks Holdings's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ginkgo Bioworks Holdings Current Deferred Revenue Chart

Ginkgo Bioworks Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial 681.89 932.24 823.17 638.16 359.74

Ginkgo Bioworks Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 688.48 532.62 462.93 359.74 268.87
MEX:DNA
54GF Score
Ginkgo Bioworks Holdings Inc MEX:DNA
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of MXN269 Mil mean?
Ginkgo Bioworks Holdings (MEX:DNA) has a Current Deferred Revenue of MXN269 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Ginkgo Bioworks Holdings and its competitors.
Is Ginkgo Bioworks Holdings' Current Deferred Revenue too high?
Ginkgo Bioworks Holdings' current Current Deferred Revenue is MXN269 Mil. Overall, Ginkgo Bioworks Holdings has a GF Score™ of 54/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ginkgo Bioworks Holdings' Current Deferred Revenue compare to RZLT and EIKN?
Ginkgo Bioworks Holdings' Current Deferred Revenue of MXN269 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Ginkgo Bioworks Holdings and its competitors. Ginkgo Bioworks Holdings's current Current Deferred Revenue is MXN269 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ginkgo Bioworks Holdings stock overvalued right now?
Based on GuruFocus' analysis, Ginkgo Bioworks Holdings (MEX:DNA) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN149.41, compared to a current price of MXN170.00 — trading 13.8% above its estimated fair value. The current Current Deferred Revenue is MXN269 Mil. Ginkgo Bioworks Holdings' overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Ginkgo Bioworks Holdings (MEX:DNA), the current Current Deferred Revenue is MXN269 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ginkgo Bioworks Holdings (MEX:DNA) Overvalued in 2026?

Based on GuruFocus' analysis, Ginkgo Bioworks Holdings stock appears to be overvalued. The current stock price of MXN170.00 is trading 13.8% above its estimated GF Value™ of MXN149.41. GuruFocus considers Ginkgo Bioworks Holdings to be Modestly Undervalued.

Key valuation signals for MEX:DNA:

  • Current Deferred Revenue: MXN269 Mil
  • GF Value™: MXN149.41 vs. price of MXN170.00 (13.8% above fair value)
  • GF Score™: 54/100 with 5 warning signs

No single metric tells the full story. See the MEX:DNA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ginkgo Bioworks Holdings Business Description

Other Exchanges DNA:USA
Address 27 Drydock Avenue, 8th Floor, Boston, MA, USA, 02210
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
54GF Score

Get the complete analysis for MEX:DNA

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN170.00
Price
MXN149.41
GF Value